Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales

The first-quarter results come as Merck shows substantial progress in preparing for Keytruda’s patent expiration in 2028.

Previous post Comcast is set to report earnings before the bell. Here’s what Wall Street expects
Next post Chip sector due a May bounce with Nvidia near ‘trough valuation,’ says Bank of America strategists